je.st
news
Tag: meeting activity
Meeting 2 Activity Instructions
2016-04-08 19:21:22| PortlandOnline
PDF Document, 166kbCategory: Meeting 2
Tags: activity
meeting
instructions
meeting activity
Findings Presented at 2015 ASCO Annual Meeting Add to Breadth of KEYTRUDA (pembrolizumab) Data; Anti-Tumor Activity Now Demonstrated in 13 Different Tumor Types
2015-06-01 14:00:00| Merck.com - Product News
Dateline City: KENILWORTH, N.J. New Data Presented at ASCO in Multiple, Difficult-to-Treat Cancers, including Small Cell Lung, Esophageal and Ovarian Cancers Registrational Studies for KEYTRUDA Ongoing in Eight Different Tumor Types KENILWORTH, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the first-time presentation of findings investigating the use of KEYTRUDA (pembrolizumab), the companys anti-PD-1 therapy, in multiple, difficult-to-treat cancers, including advanced small cell lung cancer (SCLC), esophageal cancer and ovarian cancer from the KEYNOTE-028 Phase 1b study. Language: English Contact: MerckMedia:Pamela Eisele, 267-664-0282orClaire Mulhearn, 908-200-1889orInvestors:Joseph Romanelli, 908-740-1986orJustin Holko, 908-740-1879 Ticker Slug: Ticker: MRK Exchange: NYSE read more
Tags: add
data
types
presented
Sites : [1]